Inclusion Criteria:

- Male or female subjects 18-75 years of age.

- Subjects who are recipients of HLA-identical living donor renal allografts from a
sibling and are at least 1 year post transplant, their donors and mothers.

- Subjects must be capable of understanding the purpose and risks of the study and must
sign a statement of informed consent.

Exclusion Criteria:

- GFR <40ml/min;

- diagnosis of SLE,

- Subjects with proteinuria (defined as a protein:creatinine ratio of >1 or an amount
less than this deemed significant on an individual subject basis by the principal
investigator),,

- multi-organ transplant;

- known hypersensitivity to, Prograf, Neoral, CellCept or Myfortic;

- history of documented post transplant non-compliance with medications, transplant
clinic or laboratory follow-up;

- therapy with an investigational immunosuppressive drug within 6 weeks of study entry;

- history of a psychological illness or condition such as to interfere with the
patient's ability to understand the requirements of the study;

- patients on less than 500 mg PO BID of CellCept or 360 mg PO BID of Myfortic at the
time of potential randomization,

- history of humoral rejection post transplant,

- maintenance or for cause treatment with steroids (prednisone) within 3 months of
enrollment.